[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623714":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":44,"collaborators":19,"id":46,"slug":19,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":19,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":19,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Al18F-NOTA-FAPI PET\u002FCT(PET\u002FMRI)","EXPERIMENTAL","Evaluation of dosimetry, safety, diagnostic accuracy, and clinical treatment strategy guidance ability of Al18F-NOTA-FAPI PET\u002FCT(or PET\u002FMRI) in patients with malignant tumor,cardiovascular or immune disease.",[13],"Other: Al18F-NOTA-FAPI PET\u002FCT(or PET\u002FMRI)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Al18F-NOTA-FAPI PET\u002FCT(or PET\u002FMRI)","Participants will receive an intravenous injection of Al18F-NOTA-FAPI, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline. The recommended dose is approximately 4.81 MBq\u002Fkg (0.13 mCi\u002Fkg) body weight, with variations depending on drug yield and clinical scheduling. PET\u002FCT(or PET\u002FMRI) imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Li Huo, MD","CONTACT","+86 18612672038","huoli@pumch.cn",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Xueqian Yang, MS","+86 18801349606","yangxq202508@163.com",[31],{"facility":5,"status":32,"city":33,"state":19,"zip":19,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Beijing","China",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":5,"role":23,"phone":43,"phoneExt":19,"email":25},"+86 010-69154702",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100623714",false,"NCT07400224","Clinical Application of Al18F-NOTA-FAPI-04 PET\u002FCT or PET\u002FMRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease","Inclusion Criteria:\n\n* a. Age 18 years old or above, gender not restricted. b. Have undergone a health check-up within the last 3 months (at least completed chest X-ray \u002F chest CT and abdominal B-ultrasound and other examinations), and no major diseases were found.\n\nExclusion Criteria:\n\n* As this study involves certain radiation exposure, patients who have had frequent radiation exposure due to clinical needs (those who have undergone a CT or PET\u002FCT examination once within 3 months or 1 month respectively) are not included in the study.",true,"ALL","18 Years","88 Years",{"count":56,"type":57},600,"ESTIMATED","INTERVENTIONAL",[60,61],"PHASE1","PHASE2","This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.",[64,65,66],"Hyperthyroidism, Autoimmune","Cardiovascular Abnormalities","Malignant Tumor","2026-02-03",{"date":69,"type":70},"2026-02-10","ACTUAL",{"date":72,"type":70},"2022-05-10",{"date":74,"type":57},"2028-12-31",{"name":5,"class":6},1]